T-cell receptor (TCR) recognizing MHC-MUC1 peptide complexes (TCR-MUC1)

The T-cell receptor (TCR) recognizing MHC-MUC1 peptide complexes is a specialized antigen receptor expressed on the surface of CD8+ and CD4+ T lymphocytes that specifically identifies Mucin 1 (MUC1) peptides presented by Major Histocompatibility Complex (MHC) molecules. MUC1 is a transmembrane glycoprotein that is significantly overexpressed and aberrantly glycosylated in many adenocarcinomas, such as breast, lung, and pancreatic cancers, making it a key tumor-associated antigen. These TCRs can be MHC-restricted, typically recognizing MUC1 peptides in the context of HLA-A*02:01, or in some instances, MHC-unrestricted, binding directly to the MUC1 protein core. Therapeutic approaches targeting this receptor system include TCR-engineered T-cell (TCR-T) therapies, which utilize T cells modified to express high-affinity MUC1-specific TCRs to eradicate tumor cells, and cancer vaccines like tecemotide that aim to stimulate an endogenous T-cell response. Additionally, TCR-mimetic antibodies are being developed to target the same MHC-MUC1 interface, offering a strategy to engage intracellularly derived MUC1 antigens with the precision of a T-cell receptor.

Other names

MUC1-specific T-cell receptorMUC1-restricted T-cell receptorMUC1-MHC-specific TCRMUC1-specific TCRMUC1-reactive T-cell receptor

Therapeutic agents targeting this receptor system function by either engineering T cells to express high-affinity MUC1-specific TCRs (TCR-T therapy) or by using vaccines to induce an endogenous T-cell response against MUC1 peptides presented on MHC. These interactions trigger the TCR signaling complex, leading to T-cell proliferation, cytokine release, and the targeted lysis of MUC1-expressing tumor cells.